Article: Dyad Receives United States Patent for Novel Oligonucleotide Configuration; Dyad's Novel Oligonucleotides May Lead to Treatments for Unwanted Hair Growth, Acne, and Male Pattern Baldness.

COLUMBIA, Md., and WASHINGTON, Aug. 7 /PRNewswire/ -- Dyad Pharmaceutical Corporation announced today that they have received a United States patent for sequence specific hybridization of RNA by a novel 2'-5' configuration of oligonucleotide. These oligonucleotides are joined by the 2'-5' bond connections instead of the normal 3'-5' bond connections observed in DNA and RNA. The unique property associated with 2'-5' connected oligonucleotides is in their ability to bind selectively with RNA and not with DNA. Dyad's broad patented discovery may have extensive applications in diagnostics and in anti- sense therapy.

In announcing the issuance of the patent, Dr. ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!